Annovis Bio Inc. (ANVS): Price and Financial Metrics
ANVS Price/Volume Stats
| Current price | $9.10 | 52-week high | $23.89 |
| Prev. close | $9.49 | 52-week low | $8.94 |
| Day low | $8.94 | Volume | 27,300 |
| Day high | $9.56 | Avg. volume | 55,412 |
| 50-day MA | $11.93 | Dividend yield | N/A |
| 200-day MA | $14.06 | Market Cap | 82.01M |
ANVS Stock Price Chart Interactive Chart >
Annovis Bio Inc. (ANVS) Company Bio
Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.
Latest ANVS News From Around the Web
Below are the latest news stories about ANNOVIS BIO INC that investors may wish to consider to help them evaluate ANVS as an investment opportunity.
Karuna (KRTX) Submits NDA Filing to FDA for Schizophrenia DrugIf approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. Data from three clinical studies support the FDA filing. |
Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer StudiesData from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints. |
FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney DiseaseFollowing the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States. |
Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug StudyData from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely hurt the company's chances for the drug's full approval. |
Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug EnrylazeThe approval is based on data from a phase II/III study, which showed that treatment with Jazz's (JAZZ) Enrylaze achieved sustained asparagine activity in two cancer indications. |
ANVS Price Returns
| 1-mo | -26.26% |
| 3-mo | N/A |
| 6-mo | -25.65% |
| 1-year | -33.58% |
| 3-year | 82.73% |
| 5-year | N/A |
| YTD | -32.24% |
| 2022 | -23.61% |
| 2021 | 133.16% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...